Study of a targeted radiation therapy for advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic clear cell renal cell carcinoma (a type of kidney cancer) that has come back or not responded to treatment.
- You have received at least 2 but no more than 3 prior treatments for advanced kidney cancer, including a PD-1/PD-L1 inhibitor and a VEGF-targeting therapy.
- Your cancer has gotten worse during or after your last treatment, or you could not tolerate it.
- You have at least one tumor that can be measured by a scan and that shows a specific marker (CAIX) on a special PET scan.
- You are in good overall health (able to care for yourself and up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of radiation therapy that targets kidney cancer cells. It is for people whose cancer has returned or spread after at least two prior treatments, and aims to see if it can shrink tumors and slow the disease.
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
This early-phase trial tests whether combining a targeted radiation medicine (177Lu-TLX250) with a DNA repair–blocking drug (peposertib) can shrink advanced solid tumors. It is designed for tumors that strongly show a marker called CAIX, which helps the radiation home in and may make treatment more effective.
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
This study tests a radioactive medicine (called 161Tb-PSMA) that delivers radiation directly to kidney cancer cells that have a specific marker (PSMA). It is for people whose kidney cancer has spread and has not responded to at least two prior treatments. The goal is to see if this new therapy can help shrink the cancer.
This trial tests a combination of precise radiation (SBRT) plus two drugs (anlotinib and bimepolizumab) to see if it helps control advanced kidney cancer. The goal is to shrink tumors and slow the cancer's growth.
Hear when a new ccRCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.